<DOC>
	<DOCNO>NCT01963702</DOCNO>
	<brief_summary>Platinum , fluorouracil taxane base regimen acceptable first line treatment metastatic gastric cancer . The TX XELOX regimen two common regimen use MGC . whichever regimen use , average response rate le 50 % . So rather part patient ca n't get benefit treatment . It urgent find predictive factor regimens order get high response well survival outcome .</brief_summary>
	<brief_title>A Phase II Trial Exploring Predictive Factors TX XELOX Regimen First Line Treatment MGC</brief_title>
	<detailed_description>Patients MGC treat TX XELOX regimen . Before treatment , 14 day treatment progression , blood sample collect . Primary tumor block also collect . These sample use detect predictive factor two type first line therapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Chemonaive patient metastatic , unresectable , histologically confirm gastric Gastroesophageal adenocarcinoma ; Patients receive adjuvant chemotherapy , duration last therapy relapse least longer 6 month Patient must least one measurable lesion ( RECIST 1.1 ) 18 Years 75 year Written inform consent obtain Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Patients must adequate organ marrow function define : neutrophilicgranulocyte great than/equal 1,500/mm3 ; platelet great than/equal 90,000/ mm3 ; hemoglobin great than/equal 9 gm/dL ( may transfuse maintain exceed level ) ; total bilirubin less than/equal 1.5 within institutional upper limit normal ( IULN ) ; Aspartate Transaminase ( AST , SGOT ) /Alanine transaminase ( ALT , SGPT ) less than/equal 2.5 time IULN serum creatinine le than/equal 1.5 x IULN . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 , National Cancer InstituteCommon Terminology Criteria Adverse Events ) Symptomatic metastatic brain meningeal tumor History organ allograft Patients undergoing renal dialysis chronic inflammatory bowel disease ; ileus ; genetic fructose intolerance Patients receive adjuvant chemotherapy duration last therapy less 6 month Receive previously radiotherapy measurable region Pregnancy lactate status Concurrent malignancy nonmelanoma skin cancer , situ cervix carcinoma Clinically relevant coronary artery disease history myocardial infarction within last 12 month Acute subacute intestinal occlusion history inflammatory bowel disease Any factor influence usage oral administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>predictive factor</keyword>
	<keyword>response</keyword>
	<keyword>gastric neoplasm</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>docetaxol</keyword>
	<keyword>capecitabine</keyword>
</DOC>